Search results for TNF alpha

TNF alpha Monoclonal Antibody, APC-Cy5.5 Conjugated, Bioss, bsm-0387m-apc-Cy5.5-100ul

TNF alpha Monoclonal Antibody, APC-Cy7 Conjugated, Bioss, bsm-0387m-apc-cy7-100ul

TNF alpha Monoclonal Antibody, PE-Cy5 Conjugated, Bioss, bsm-0387m-pe-cy5-100ul

TNF alpha Monoclonal Antibody, PE-Cy5.5 Conjugated, Bioss, bsm-0387m-pe-Cy5.5-100ul

TNF alpha Monoclonal Antibody, PE-Cy7 Conjugated, Bioss, bsm-0387m-pe-cy7-100ul

TNF alpha Monoclonal Antibody, PerCP-Cy5.5 Conjugated, Bioss, bsm-0387m-percp-Cy5.5-100ul

TNF alpha Monoclonal Antibody, PerCP-Cy7 Conjugated, Bioss, bsm-0387m-percp-cy7-100ul

Certolizumab Biosimilar – Anti-TNF-Alpha mAb – Research Grade, ProteoGenix, PX-TA1024

Description of Certolizumab Biosimilar - Anti-TNF-Alpha mAb - Research Grade Certolizumab Biosimilar: A Promising Anti-TNF-Alpha Monoclonal Antibody for Therapeutic Targeting Certolizumab Biosimilar is a novel monoclonal antibody (mAb) that has gained significant attention in the field of immunotherapy due to its potential as a therapeutic agent for various inflammatory and autoimmune diseases. This biosimilar is a highly specific and potent inhibitor of tumor necrosis factor-alpha (TNF-α), a key pro-inflammatory cytokine involved in the pathogenesis of several chronic inflammatory disorders. In this article, we will delve into the structure, activity, and potential applications of Certolizumab Biosimilar as an anti-TNF-α mAb in research settings. Structure of Certolizumab Biosimilar Certolizumab Biosimilar is a recombinant, fully humanized IgG1 monoclonal antibody that is produced by a mammalian cell expression system. It is composed of two heavy chains and two light chains, each containing a variable and constant region. The variable region of Certolizumab Biosimilar specifically binds to TNF-α, while the constant region mediates effector functions such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). One unique feature of Certolizumab Biosimilar is the absence of the Fc region, which is responsible for effector functions in other mAbs. This is achieved by replacing the Fc region with a 40 kDa polyethylene glycol (PEG) molecule, resulting in a smaller molecular weight of 90 kDa compared to other anti-TNF-α mAbs. This modification not only enhances the half-life and stability of the antibody, but also reduces the risk of immunogenicity and potential adverse effects. Activity of Certolizumab Biosimilar The main mechanism of action of Certolizumab Biosimilar is the neutralization of TNF-α, a pro-inflammatory cytokine that plays a crucial role in the pathogenesis of various diseases, including rheumatoid arthritis, psoriasis, Crohn’s disease, and ankylosing spondylitis. TNF-α is known to induce inflammation, tissue damage, and bone erosion by activating immune cells and promoting the production of other inflammatory cytokines. By binding to TNF-α, Certolizumab Biosimilar prevents its interaction with its receptors and inhibits downstream signaling pathways, thereby reducing inflammation and disease progression. Moreover, the PEGylation of Certolizumab Biosimilar also contributes to its activity by prolonging its half-life and reducing its clearance from the body. This allows for a longer duration of action and potentially lower dosing frequency compared to other anti-TNF-α mAbs, making it a more convenient and cost-effective option for patients. Applications of Certolizumab Biosimilar Certolizumab Biosimilar has been extensively studied and has shown promising results in clinical trials for various inflammatory and autoimmune diseases. In particular, it has been approved for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn’s disease in several countries, including Europe and Japan. It is also being investigated for its potential in other indications such as ulcerative colitis, axial spondyloarthritis, and non-infectious uveitis. In research settings, Certolizumab Biosimilar is widely used as a tool to study the role of TNF-α in disease pathogenesis and to evaluate the efficacy of anti-TNF-α therapies. Its unique structure and mechanism of action provide a valuable platform for developing new and improved anti-TNF-α mAbs with enhanced properties and reduced side effects. Conclusion In summary, Certolizumab Biosimilar is a promising anti-TNF-α monoclonal antibody with a unique

Infliximab Biosimilar – Anti-TNF-alpha mAb – Research Grade, ProteoGenix, PX-TA1009

Description of Infliximab Biosimilar - Anti-TNF-alpha mAb - Research Grade General information about Infliximab Infliximab, a chimeric monoclonal antibody, is a medication used to treat a number of autoimmune diseases. This includes Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behçet’s disease. It is given by slow injection into a vein, typically at six- to eight-week intervals. Infliximab was originally developed in mice as a mouse antibody. Because humans have immune reactions to mouse proteins, the mouse common domains were replaced with similar human antibody domains. They are monoclonal antibodies and have identical structures and affinities to the target. Because they are a combination of mouse and human antibody amino acid sequences, they are called a “chimeric monoclonal antibody”. This product is for research use only.

Anti-Human TNFa/TNF-alpha Nanobody (SAA1163) (HF879033), abinScience, HF879033